GB2547179A - Genetic construct - Google Patents

Genetic construct Download PDF

Info

Publication number
GB2547179A
GB2547179A GB1518911.1A GB201518911A GB2547179A GB 2547179 A GB2547179 A GB 2547179A GB 201518911 A GB201518911 A GB 201518911A GB 2547179 A GB2547179 A GB 2547179A
Authority
GB
United Kingdom
Prior art keywords
genetic construct
seq
construct according
variant
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1518911.1A
Other languages
English (en)
Other versions
GB201518911D0 (en
Inventor
Widdowson Peter
Martin Keith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quethera Ltd
Original Assignee
Quethera Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quethera Ltd filed Critical Quethera Ltd
Priority to GB1518911.1A priority Critical patent/GB2547179A/en
Publication of GB201518911D0 publication Critical patent/GB201518911D0/en
Priority to HUE16788748A priority patent/HUE056911T2/hu
Priority to JP2018540229A priority patent/JP7073264B2/ja
Priority to ES16788748T priority patent/ES2886009T3/es
Priority to LTEPPCT/GB2016/053319T priority patent/LT3368678T/lt
Priority to EP21187396.3A priority patent/EP3985119A1/en
Priority to EP16788748.8A priority patent/EP3368678B1/en
Priority to US15/762,089 priority patent/US10342880B2/en
Priority to PL16788748T priority patent/PL3368678T3/pl
Priority to RU2018115760A priority patent/RU2734678C2/ru
Priority to RS20211108A priority patent/RS62460B1/sr
Priority to CA3001036A priority patent/CA3001036C/en
Priority to CN201680062516.6A priority patent/CN108350467B/zh
Priority to PCT/GB2016/053319 priority patent/WO2017072498A1/en
Priority to MX2018005286A priority patent/MX2018005286A/es
Priority to HK18111561.6A priority patent/HK1252168B/en
Priority to SI201631325T priority patent/SI3368678T1/sl
Priority to KR1020187011772A priority patent/KR102819739B1/ko
Priority to DK16788748.8T priority patent/DK3368678T3/da
Priority to PT167887488T priority patent/PT3368678T/pt
Priority to AU2016344508A priority patent/AU2016344508B2/en
Priority to SM20210520T priority patent/SMT202100520T1/it
Priority to HRP20211407TT priority patent/HRP20211407T1/hr
Publication of GB2547179A publication Critical patent/GB2547179A/en
Priority to US16/436,676 priority patent/US11471539B2/en
Priority to CY20211100785T priority patent/CY1124588T1/el
Priority to JP2022078299A priority patent/JP7503590B2/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
GB1518911.1A 2015-10-26 2015-10-26 Genetic construct Withdrawn GB2547179A (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GB1518911.1A GB2547179A (en) 2015-10-26 2015-10-26 Genetic construct
HRP20211407TT HRP20211407T1 (hr) 2015-10-26 2016-10-25 Genetska konstrukcija
CN201680062516.6A CN108350467B (zh) 2015-10-26 2016-10-25 基因构建体
MX2018005286A MX2018005286A (es) 2015-10-26 2016-10-25 Constructo genetico.
ES16788748T ES2886009T3 (es) 2015-10-26 2016-10-25 Construcción genética
LTEPPCT/GB2016/053319T LT3368678T (lt) 2015-10-26 2016-10-25 Genetinis konstruktas
EP21187396.3A EP3985119A1 (en) 2015-10-26 2016-10-25 Recombinant vector
EP16788748.8A EP3368678B1 (en) 2015-10-26 2016-10-25 Genetic construct
US15/762,089 US10342880B2 (en) 2015-10-26 2016-10-25 Genetic construct
PL16788748T PL3368678T3 (pl) 2015-10-26 2016-10-25 Konstrukt genetyczny
RU2018115760A RU2734678C2 (ru) 2015-10-26 2016-10-25 Генетическая конструкция
RS20211108A RS62460B1 (sr) 2015-10-26 2016-10-25 Genetski konstrukt
CA3001036A CA3001036C (en) 2015-10-26 2016-10-25 Recombinant vectors encoding tyrosine kinase receptor b and agonists thereof
HUE16788748A HUE056911T2 (hu) 2015-10-26 2016-10-25 Genetikai konstrukció
PCT/GB2016/053319 WO2017072498A1 (en) 2015-10-26 2016-10-25 Genetic construct
JP2018540229A JP7073264B2 (ja) 2015-10-26 2016-10-25 遺伝子構築物
HK18111561.6A HK1252168B (en) 2015-10-26 2016-10-25 Genetic construct
SI201631325T SI3368678T1 (sl) 2015-10-26 2016-10-25 Genetski konstrukt
KR1020187011772A KR102819739B1 (ko) 2015-10-26 2016-10-25 유전적 작제물
DK16788748.8T DK3368678T3 (da) 2015-10-26 2016-10-25 Genetisk konstrukt
PT167887488T PT3368678T (pt) 2015-10-26 2016-10-25 Construção genética
AU2016344508A AU2016344508B2 (en) 2015-10-26 2016-10-25 Genetic construct
SM20210520T SMT202100520T1 (it) 2015-10-26 2016-10-25 Costrutto genico
US16/436,676 US11471539B2 (en) 2015-10-26 2019-06-10 Genetic construct
CY20211100785T CY1124588T1 (el) 2015-10-26 2021-09-06 Γενετικο κατασκευασμα
JP2022078299A JP7503590B2 (ja) 2015-10-26 2022-05-11 遺伝子構築物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1518911.1A GB2547179A (en) 2015-10-26 2015-10-26 Genetic construct

Publications (2)

Publication Number Publication Date
GB201518911D0 GB201518911D0 (en) 2015-12-09
GB2547179A true GB2547179A (en) 2017-08-16

Family

ID=55130230

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1518911.1A Withdrawn GB2547179A (en) 2015-10-26 2015-10-26 Genetic construct

Country Status (21)

Country Link
US (2) US10342880B2 (cg-RX-API-DMAC7.html)
EP (2) EP3985119A1 (cg-RX-API-DMAC7.html)
JP (2) JP7073264B2 (cg-RX-API-DMAC7.html)
KR (1) KR102819739B1 (cg-RX-API-DMAC7.html)
CN (1) CN108350467B (cg-RX-API-DMAC7.html)
AU (1) AU2016344508B2 (cg-RX-API-DMAC7.html)
CY (1) CY1124588T1 (cg-RX-API-DMAC7.html)
DK (1) DK3368678T3 (cg-RX-API-DMAC7.html)
ES (1) ES2886009T3 (cg-RX-API-DMAC7.html)
GB (1) GB2547179A (cg-RX-API-DMAC7.html)
HR (1) HRP20211407T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056911T2 (cg-RX-API-DMAC7.html)
LT (1) LT3368678T (cg-RX-API-DMAC7.html)
MX (1) MX2018005286A (cg-RX-API-DMAC7.html)
PL (1) PL3368678T3 (cg-RX-API-DMAC7.html)
PT (1) PT3368678T (cg-RX-API-DMAC7.html)
RS (1) RS62460B1 (cg-RX-API-DMAC7.html)
RU (1) RU2734678C2 (cg-RX-API-DMAC7.html)
SI (1) SI3368678T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100520T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017072498A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2999279A1 (en) 2015-10-01 2017-04-06 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
GB201705484D0 (en) * 2017-04-05 2017-05-17 Quethera Ltd Genetic construct
KR20200057051A (ko) * 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
MX2020004035A (es) 2017-10-20 2020-11-09 Res Inst Nationwide Childrens Hospital Métodos y materiales para terapia génica con nt-3.
JP2021507723A (ja) * 2017-12-05 2021-02-25 ユニバーシティ オブ ワシントンUniversity of Washington 視細胞における治療遺伝子の機能的発現を増強するための組成物および方法
CN108250288A (zh) * 2018-01-17 2018-07-06 吉林省农业科学院 一种叶绿体表达的脑源性神经营养因子hBDNFb蛋白及其制备方法
CN109022487A (zh) * 2018-08-15 2018-12-18 上海市第人民医院 一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
US12534739B2 (en) 2018-10-11 2026-01-27 Decibel Therapeutics, Inc. AAV1 vectors and uses thereof for treatment of otic indications
JP2022514863A (ja) * 2018-12-19 2022-02-16 ヴェルサメブ アーゲー タンパク質をコードするrna
WO2020179844A1 (ja) * 2019-03-04 2020-09-10 公益財団法人東京都医学総合研究所 Trk断片をコードする核酸構築物、及びその利用
SG11202108864UA (en) * 2019-03-06 2021-09-29 Generation Bio Co Closed-ended dna (cedna) and immune modulating compounds
US12649930B2 (en) 2019-03-27 2026-06-09 Sigilon Therapeutics, Inc. Compositions, devices, and methods for treating Fabry disease
CA3133357A1 (en) * 2019-03-27 2020-10-01 Sigilon Therapeutics, Inc. Compositions, devices and methods for factor vii therapy
US20230038502A1 (en) 2019-06-11 2023-02-09 Shire Human Genetic Therapies, Inc. Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
WO2021011841A1 (en) * 2019-07-18 2021-01-21 Lysogene Compositions and methods for the treatment of sanfilippo disease and other disorders
RU2719013C1 (ru) * 2019-09-25 2020-04-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Генно-инженерная конструкция для стимуляции посттравматической регенерации периферических нервов
JP7713130B2 (ja) 2019-09-30 2025-07-25 イーライ リリー アンド カンパニー 遺伝性難聴の処置のためのアデノ随伴ウイルス(aav)システム
WO2021081280A1 (en) 2019-10-23 2021-04-29 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
EP4263614A1 (en) 2020-12-16 2023-10-25 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
EP4297800A1 (en) * 2021-02-26 2024-01-03 Icahn School of Medicine at Mount Sinai Method for decreasing degeneration of retinal ganglion cells
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
CN118256562A (zh) * 2022-12-26 2024-06-28 科辉智药(深圳)新药研究中心有限公司 一种用于中枢神经系统疾病治疗的基因序列构建体及其应用
KR20250142340A (ko) 2023-02-02 2025-09-30 퀘세라 리미티드 재조합 아데노-부속 바이러스 벡터
CN118534135A (zh) * 2024-06-07 2024-08-23 中国人民解放军联勤保障部队第九二四医院 一种中枢性肥胖抵抗标志物及其检测方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016242A1 (en) * 1996-10-16 1998-04-23 Regeneron Pharmaceuticals, Inc. Method of enhancing the delivery of growth factors
US20040110711A1 (en) * 2001-02-22 2004-06-10 University Of Maryland, Baltimore Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
US20110288160A1 (en) * 2008-03-27 2011-11-24 The Ohio State University Research Foundation Treatment of Metabolic-Related Disorders Using Hypothalamic Gene Transfer of BDNF and Compositions Therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
AU3418199A (en) * 1998-04-20 1999-11-08 Koninklijke Nederlandse Akademie Van Wetenschappen Use of viral vectors for treatment of the injured peripheral and central nervoussystem
DK1343532T3 (da) * 2000-12-19 2013-07-29 Res Dev Foundation Lentivirusvektormedieret genoverførsel og anvendelser deraf
FR2906533B1 (fr) * 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
CN103614416B (zh) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016242A1 (en) * 1996-10-16 1998-04-23 Regeneron Pharmaceuticals, Inc. Method of enhancing the delivery of growth factors
US20040110711A1 (en) * 2001-02-22 2004-06-10 University Of Maryland, Baltimore Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
US20110288160A1 (en) * 2008-03-27 2011-11-24 The Ohio State University Research Foundation Treatment of Metabolic-Related Disorders Using Hypothalamic Gene Transfer of BDNF and Compositions Therefor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
International Journal of Nanomedicine (Apr 2015); Vol 3245-3267, "Targeted delivery of brain-derived neurotrophic...", Khalin et al *
IOVS (2003); Vol 44, pp 4357-4365, "Gene therapy with brain-derived neurotrophic factor...", Martin et al *
IOVS (2005); Vol 46 (Suppl.), p 4149, "Transplantation of brain-derived neurotrophic factor...", Iseya et al *
Journal of Neuroscience (2002); Vol 22, pp 3977-3986, "TrkB gene transfer protects retinal ganglion...", Cheng et al *

Also Published As

Publication number Publication date
EP3368678A1 (en) 2018-09-05
JP7073264B2 (ja) 2022-05-23
KR20180081503A (ko) 2018-07-16
DK3368678T3 (da) 2021-09-13
HK1252168A1 (zh) 2019-05-17
KR102819739B1 (ko) 2025-06-13
RU2734678C2 (ru) 2020-10-21
WO2017072498A1 (en) 2017-05-04
CN108350467B (zh) 2022-06-03
GB201518911D0 (en) 2015-12-09
SI3368678T1 (sl) 2021-12-31
HUE056911T2 (hu) 2022-04-28
US10342880B2 (en) 2019-07-09
LT3368678T (lt) 2021-11-10
CN108350467A (zh) 2018-07-31
JP7503590B2 (ja) 2024-06-20
US20180353621A1 (en) 2018-12-13
US11471539B2 (en) 2022-10-18
RS62460B1 (sr) 2021-11-30
ES2886009T3 (es) 2021-12-16
PT3368678T (pt) 2021-09-15
SMT202100520T1 (it) 2021-11-12
JP2022116040A (ja) 2022-08-09
AU2016344508A1 (en) 2018-04-19
EP3368678B1 (en) 2021-07-28
RU2018115760A (ru) 2019-11-28
MX2018005286A (es) 2018-09-21
HRP20211407T1 (hr) 2021-12-10
PL3368678T3 (pl) 2021-12-13
AU2016344508B2 (en) 2022-10-06
JP2018535696A (ja) 2018-12-06
CA3001036A1 (en) 2017-05-04
CY1124588T1 (el) 2022-03-24
US20200040360A1 (en) 2020-02-06
EP3985119A1 (en) 2022-04-20
RU2018115760A3 (cg-RX-API-DMAC7.html) 2020-03-19

Similar Documents

Publication Publication Date Title
JP7503590B2 (ja) 遺伝子構築物
ES2881176T3 (es) Construcción genética para uso en el tratamiento del trastorno neurodegenerativo o accidente cerebrovascular
CN106795224A (zh) 用促滤泡素抑制素多肽治疗病症的方法和组合物
CN110869386A (zh) 重组神经生长因子的组合物和方法
KR20220063190A (ko) 안과 장애의 치료 또는 예방에 사용하기 위한 제제
EP2983690B1 (en) Neuropeptide y-derived peptides
US20240132914A1 (en) Viral vector-based gene therapy for ocular conditions
CA3001036C (en) Recombinant vectors encoding tyrosine kinase receptor b and agonists thereof
WO2022046919A2 (en) Compositions and methods for the treatment of ocular neuroinflammation
HK1252168B (en) Genetic construct
IL321968A (en) Recombinant adeno-associated virus vector
JP2006516112A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)